Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28582
Title: | Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study. | Austin Authors: | Khor, Yet H ;Gutman, Lawrence;Abu Hussein, Nebal;Johannson, Kerri A;Glaspole, Ian N;Guler, Sabina A;Funke-Chambour, Manuela;Geiser, Thomas;Goh, Nicole S L ;Ryerson, Christopher J | Affiliation: | Respiratory and Sleep Medicine Institute for Breathing and Sleep Department of Respiratory Medicine, Alfred Health, Melbourne, VIC, Australia Department of Medicine, Monash University, Melbourne, VIC, Australia Department of Medicine, University of Calgary, Calgary, AB, Canada Department of Medicine, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada Department of Pulmonary Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland Centre for Heart Lung Innovation, Providence Health Care, Vancouver, BC, Canada Department of Medicine, University of British Columbia, Vancouver, BC, Canada Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia |
Issue Date: | Sep-2021 | Date: | 2021-04-24 | Publication information: | Chest 2021; 160(3): 994-1005 | Abstract: | Hypoxemia is a cardinal feature of fibrotic interstitial lung disease (ILD). The incidence, progression, and prognostic significance of hypoxemia in patients with fibrotic ILD currently is unknown. What are the epidemiologic features of hypoxemia and its additive prognostic value in a current risk prediction model of fibrotic ILD? We identified 848 patients with fibrotic ILD (258 with idiopathic pulmonary fibrosis [IPF]) in five prospective ILD registries from Australia, Canada, and Switzerland. Cumulative incidence of exertional and resting hypoxemia from the time of diagnosis was estimated at 1-year intervals in patients with baseline 6-min walk tests, adjusted for competing risks of death and lung transplantation. Likelihood ratio tests were used to determine the prognostic significance of exertional and resting hypoxemia for 1-year mortality or transplantation when added to the ILD-GAP model. The cohort was divided into derivation and validation subsets to evaluate performance characteristics of the extended model (the ILD-GAP-O2 model), which included oxygenation status as a predictor. The 1-, 2-, and 5-year overall cumulative incidence was 6.1%, 17.3%, and 40.1%, respectively, for exertional hypoxemia and 2.4%, 5.6%, and 16.5%, respectively, for resting hypoxemia, which were significantly higher in patients with IPF compared with patients without IPF (P < .001 for both). Addition of exertional or resting hypoxemia to the ILD-GAP model improved 1-year mortality and transplantation prediction (P < .001 for both). The ILD-GAP-O2 model showed improved discrimination (C-index, 0.80 vs 0.75) and model fit (Akaike information criteria, 400 vs 422) in the validation cohort, with comparable calibration. Patients with IPF have higher cumulative incidence of exertional and resting hypoxemia than patients without IPF. The extended ILD-GAP-O2 model provides additional risk stratification for 1-year prognosis in fibrotic ILD. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/28582 | DOI: | 10.1016/j.chest.2021.04.037 | ORCID: | 0000-0002-5434-9342 0000-0003-2065-4346 |
Journal: | Chest | PubMed URL: | 33905679 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/33905679/ | Type: | Journal Article | Subjects: | hypoxemia idiopathic pulmonary fibrosis interstitial lung disease oxygen therapy |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.